At Inflammatix, we are reimagining diagnostics

Inflammatix will create and commercialize best-in-class host-response diagnostics to resolve major clinical and public health challenges.

Better patient care is at the core of what we do. We achieve better patient care through our innovative approach to developing diagnostics–our tests read the patient’s immune system to help us understand the cause of infection and the degree of its severity. Armed with this knowledge, the clinician can treat the patient appropriately and within minutes.

Precision medicine on demand

There is a critical unmet need for quickly and accurately characterizing infections in patients who are acutely ill. Our expert bioinformatics and assay development teams are building a host response-based diagnostics pipeline that includes tests for acute infection and sepsis, emerging infectious diseases, autoimmune diseases, tropical infections, transplant rejection and other conditions.

We are initially focused on developing tests for acute bacterial infections, viral infections, and sepsis based on patent-pending biomarkers exclusively licensed from Stanford University.



Tim Sweeney, MD, PhD
Tim Sweeney, MD, PhDCo-Founder and CEO
Jonathan Romanowsky
Jonathan RomanowskyCo-Founder and Chief Business Officer
Purvesh Khatri, PhD
Purvesh Khatri, PhDCo-Founder and Chief Scientist
Oliver Liesenfeld, MD
Oliver Liesenfeld, MDChief Medical Officer
Joao Fonseca, PhD
Joao Fonseca, PhDChief Technology Officer
Ljubomir Buturovic, PhD
Ljubomir Buturovic, PhDVice President of Machine Learning
Paul Fleming, PhD
Paul Fleming, PhDVice President of Engineering
Diana Lane
Diana LaneVice President of Quality Assurance and Regulatory Affairs